Caki-1 is a human clear cell renal cell carcinoma (ccRCC) line that displays epithelial morphology and grows in adherent culture. When grown on transwell filters, these cells form a polarized monolayer with microvilli on the apical surface and display characteristic features of the proximal tubule epithelium. In addition, the Caki-1 cells are also a useful model to study renal cancer. They are more sensitive to 5-fluorouracil and sorafenib (multi-kinase inhibitor of VEGFRs 1-3, PDGFR-b and Raf-1) than the Caki-2 cells. The Caki-1 cells express wildtype von Hippel-Lindau (VHL) tumor-suppressor protein and are known to form tumors in immunocompromised mice.
This cell line was established in 1971 from a metastatic site (skin) in a 49-year-old Caucasian male with clear cell carcinoma of the kidney.
- Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Glube N et al. (2007) Caki-1 cells represent an in vitro model system for studying the human proximal tubule epithelium. Experimental Nephrology 107: e47–e56 (PubMed ID: 17804913)
- Miyake M et al. (2012) 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncology Letters 3: 1195–1202 (PubMed ID: 22783417)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, attached here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to TRMOTDRTM@mskcc.org. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact MSK’s Tangible Materials team at TRMOTDRTM@mskcc.org.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com.